Loading candles…
Sanofi Consumer Healthcare India Ltd is an Indian pharmaceutical and consumer healthcare company incorporated in 2023 following its demerger from Sanofi India Limited. As a division of the global pharmaceutical company Sanofi, it operates as a standalone entity focusing on manufacturing and trading drugs and pharmaceutical products, primarily over-the-counter and consumer healthcare items. The company's portfolio spans business segments including self-care, allergy, digestive wellness, pain care, and multivitamins. It manages legacy brands that hold leadership positions in their therapeutic categories and employs a hybrid model combining prescription-driven demand with consumer self-choice.
| Unaudited Results - Q4-FY26 | To consider and approve the Unaudited Financial Results of the Company for the quarter ended March 31, 2026 | 28 Apr 2026 |
| Audited Results - Q3 & FY25 | To consider and approve the Audited Financial Statements for the Quarter and Financial Year ended December 31, 2025 | 25 Feb 2026 |
| Dividend | To consider recommendation of dividend, if any, for the Financial Year ended 31st December 2025 at Board Meeting to be held on Wednesday, 25th February 2026. | 25 Feb 2026 |
| Unaudited Results - Q2-FY25 | To consider and approve the Unaudited Financial Results for the quarter and nine months ended 30th September 2025 | 12 Nov 2025 |
| Unaudited Results - Q1 & FY25 | To consider and approve the Unaudited Financial Results for the quarter and half-year ended 30th June 2025 | 4 Aug 2025 |
| Unaudited Results - Q4-FY25 | To consider and approve the Unaudited Financial Results for the Quarter ended 31st March 2025 | 2 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.